Abstract

The present invention provides a polypeptide comprising a heavy-chain variable region (VH) domain and a light-chain variable region (VL) domain linked to each other through a peptide linker, the peptide linker comprising the amino acid sequence represented by SEQ ID NO: 1 or NO: 2.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided is a particle analysis system with which particles in a sample solution can be analyzed with high accuracy. A particle analysis system 100A comprises, as main parts: a particle purification device 1A; a sample solution supply unit 2 that supplies a sample solution containing particles to be analyzed to the particle purification device 1A; an extraction liquid supply unit 3 that supplies an extraction liquid to the particle purification device 1A; and an analysis device 4 that analyzes particles contained in the sample solution discharged from the particle purification device 1A. The particle purification device 1A extracts and removes dissolved ions from a sample solution containing particles and dissolved ions, by passing the dissolved ions through an ion permeable membrane. The analysis device 4 is an ICP-MS device, and can perform particle analysis by a single particle inductively coupled plasma mass spectrometry method.

IPC Classes  ?

• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• B01D 61/42 - ElectrodialysisElectro-osmosis
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/10 - Ion sourcesIon guns

Abstract

This pulse generation circuit is provided with: a capacitor that has one end connected to a power supply and the other end connected to a ground potential; a transformer that has one end of the primary side connected to the one end of the capacitor and the secondary side connected to a load; an inductor that has one end connected to the other end of the primary side of the transformer; a switching element that is connected between the other end of the inductor and the ground potential; a diode that has a cathode connected to the other end on the primary side of the transformer and an anode connected to the ground potential; and a control circuit that controls an ON-state and an OFF-state of the switching element. The control circuit controls the switching element to be turned ON, and controls the switching element to be turned OFF during a period in which the direction of the current flowing to the primary side of the transformer is reversed after the current flows to the primary side of the transformer.

IPC Classes  ?

• H03K 3/53 - Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback
• H02M 9/04 - Conversion of DC or AC input power into surge output power with DC input power using capacitative stores
• H05H 1/46 - Generating plasma using applied electromagnetic fields, e.g. high frequency or microwave energy

Abstract

This method for producing a deuterium-labeled compound is characterized by comprising: supplying a proton supply source and heavy water to the anode side of a membrane electrode assembly including an electrode and a proton conductive membrane; supplying a compound to be deuterated to the cathode side of the membrane electrode assembly; and energizing the membrane electrode assembly to deuterate the compound on the cathode side.

IPC Classes  ?

• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07B 61/00 - Other general methods
• C07C 5/00 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
• C07C 15/14 - Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
• C07C 15/48 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals monocyclic the hydrocarbon substituent containing a carbon-to-carbon triple bond
• C07C 17/00 - Preparation of halogenated hydrocarbons
• C07C 19/04 - Chloroform
• C07C 29/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
• C07C 31/04 - Methanol
• C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
• C07C 39/04 - Phenol
• C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
• C07C 45/61 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups
• C07C 47/54 - Benzaldehyde
• C07C 47/542 - Alkylated benzaldehydes
• C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
• C07C 51/347 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups
• C07C 57/32 - Phenylacetic acid
• C25B 3/01 - Products
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded

Abstract

In the conventional eFPGAs, there have been two challenges: the first one being size reduction of the logic cells to improve the implemented logic density, and the second one being minimization of the speed difference with the ASIC. According to the present embodiment, there is provided a method for configuring a programmable logic circuit represented by a gate-level netlist, wherein this is done by assigning the gate-level netlist to a 4-input, 3-output combinational logic cell, which is composed of a combination of 3 of 2-input (m-input) basic logic cells, wherein the combinational logic cell covers 3(n) nodes constituting a graph of the netlist.

IPC Classes  ?

• H03K 19/17736 - Structural details of routing resources
• H03K 19/17704 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using elementary logic circuits as components arranged in matrix form the logic functions being realised by the interconnection of rows and columns

Abstract

The present invention provides a therapeutic agent for refractory viral infections, etc., which is capable of reducing or eliminating cccDNA from hepatocytes. The therapeutic agent for refractory viral infections according to the present invention is characterized by comprising a complex encapsulating poly-I or a poly-I analog and poly-C or a poly-C analog within a drug carrier useful for drug delivery into cells, wherein the surface of the carrier is conjugated with a molecule imparting the ability to accumulate in hepatocytes.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/21 - Interferons
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/20 - Antivirals for DNA viruses

Abstract

A device for producing an ionic liquid or an ionic liquid raw material includes a reactor having a first space that is in contact with an anodic electrode part and a first ion exchange membrane part and that accommodates a first liquid, a second space that is in contact with the first ion exchange membrane part and a second ion exchange membrane part and that accommodates a second liquid, and a third space that is in contact with the second ion exchange membrane part and a cathodic electrode part and that accommodates a third liquid, the first space, the second space, and the third space being stacked in the order presented, wherein the ion exchange membrane parts both use a positive ion exchange membrane or a negative ion exchange membrane.

IPC Classes  ?

• B01D 61/42 - ElectrodialysisElectro-osmosis
• C25B 9/21 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms two or more diaphragms
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

A new gene that provides a difference in resistance between a plant parasitic nematode resistant rice variety ARC10313 and a plant parasitic nematode intolerance variety T65 is found and a plant parasitic nematode controlling agent based on the new gene is provided.　Provided is a plant parasitic nematode controlling agent comprising a polypeptide having any of amino acid sequences represented by: (a) the amino acid sequence represented by SEQ ID NO: 13; (b) an amino acid sequence resulting from deletion, substitution, or addition of one or more amino acids in the amino acid sequence represented by SEQ ID NO: 13; or (c) an amino acid sequence having an identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 13, or a fragment of said polypeptide.

IPC Classes  ?

• A01N 37/46 - N-acyl derivatives
• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A01P 5/00 - Nematocides
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

[Problem] To provide a novel pharmaceutical composition that can be used for the induction of an immune response to an HTLV-1. [Solution] A pharmaceutical composition according to the present disclosure comprises: a human T-cell leukemia virus type-1 (HTLV-1) antigenic Gag protein p15 (Gag p15) or an immunogenic fragment thereof, a Gag protein p19 (Gag p19) or an immunogenic fragment thereof, and/or a Gag protein p24 (Gag p24) or an immunogenic fragment thereof; and a pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/04 - Immunostimulants
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 15/48 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided is a method which is for analyzing ionic components in pure water and in which sample ultrapure water is concentrated and analyzed by an analysis means, the method being characterized in that the sample ultrapure water is concentrated by means of an electrodialyzer. The electrodialyzer is a second electrodialyzer (20) in which sample ultrapure water is passed through a first generation chamber (27), high-purity nitric acid aqueous solution is passed through a second generation chamber (28), and concentrated water for analysis is extracted from the second generation chamber (28). The high-purity nitric acid aqueous solution passing through the second generation chamber (28) is generated by dialyzing a potassium nitrate aqueous solution by a first electrodialyzer (10).

IPC Classes  ?

• G01N 33/18 - Water
• G01N 1/40 - Concentrating samples

Abstract

[Problem] A composition and a method that can be used to induce an immune response to HTLV-1 are needed. [Solution] The present invention relates to a lipid complex in which at least one nucleic acid selected from a nucleic acid containing a polynucleotide that encodes an immunogenic fragment of a human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein, a nucleic acid containing a polynucleotide that encodes an immunogenic fragment of an HTLV-1 antigenic Tax protein, and a nucleic acid containing a polynucleotide that encodes an immunogenic fragment an HTLV-1 antigenic HBZ protein is encapsulated in a lipid.

IPC Classes  ?

• C12N 15/48 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 37/04 - Immunostimulants
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

This determination assistance system comprises: a storage device that stores a trained model obtained by performing learning processing by using a plurality of writing information items indicating information on writing when subjects write by using a pen-shaped object, and a plurality of correct information items each indicating types of mental disorders of the subjects; a determination unit that acquires a writing information item indicating information on writing when a target person performs writing by using the pen-shaped object, and determines the type of mental disorder of the target person by using the writing information item and the trained model; and an output unit that outputs the determination result of the determination unit.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The purpose is to provide a new crosslinked product that can be synthesized easily and can constitute a material having extensibility, self-repairing properties, and shape memory properties. Also provided are a hydrogel containing the crosslinked product and a film containing the crosslinked product.　Provided is a crosslinked product in which a high-molecular-weight water-soluble polymer has been crosslinked by tannic acid, wherein the high-molecular-weight water-soluble polymer has a constituent unit containing a group G capable of forming a hydrogen bond with tannic acid, and the weight-average molecular weight is 50 kDa or more. The hydrogel contains the crosslinked product and water. The film contains the crosslinked product.

IPC Classes  ?

• C08K 5/134 - Phenols containing ester groups
• C08F 8/00 - Chemical modification by after-treatment
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08J 3/075 - Macromolecular gels
• C08J 5/18 - Manufacture of films or sheets
• C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08L 71/02 - Polyalkylene oxides
• C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity

Abstract

The purpose of the present invention is to provide a superovulation induction method for rats.　The present invention provides a method for inducing superovulation, the method being characterized by simultaneously administering an anti-inhibin antibody and equine chorionic gonadotropin (eCG) to female rats under 6 weeks of age and then administering human chorionic gonadotropin (hCG). Moreover, the present invention provides an in-vitro fertilization method using ova produced by the method of the present invention. The methods according to the present invention are applicable to various strains of rats.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
• C12N 5/075 - OocytesOogonia

Abstract

An image processing method includes: a step of creating, by a blood vessel mask creation unit, a blood vessel mask image by removing a punctate low signal intensity, removing a linear low signal intensity, extracting the linear low signal intensity, removing a punctate high signal intensity, removing a linear high signal intensity, and extracting the linear high signal intensity from an image obtained from a magnetic resonance signal intensity in which a region corresponding to a blood vessel is enhanced with respect to an MRI image; and a step of generating, by a mask processing unit, an image in which a blood vessel structure is removed using the blood vessel mask image from a phase difference enhanced image created from the MRI image.

IPC Classes  ?

• G06T 7/11 - Region-based segmentation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G06T 7/00 - Image analysis
• G06T 7/155 - SegmentationEdge detection involving morphological operators
• G06T 7/174 - SegmentationEdge detection involving the use of two or more images

Abstract

An object of the present invention is to provide a novel preventive or therapeutic agent for muscular atrophy. The present invention provides a preventive or therapeutic agent for muscular atrophy containing a Dll4 function inhibitor as an active ingredient. The Dll4 function inhibitor is selected from the group consisting of a binding inhibitor between Dll4 and Notch2, a Dll4 expression inhibitor, or an inhibitor of binding of collagen to LL4.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, for use in inhibiting metallo-β-lactamases.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61P 31/04 - Antibacterial agents

Abstract

A culture medium for the expansion of mammalian hematopoietic stem cells, the culture medium containing a glutamic acid dehydrogenase inhibitor as an active ingredient.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 7/06 - Antianaemics
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

A dispersion of exfoliated particles which includes at least one nitrogen-containing basic compound (A) which is a tertiary amine or a quaternary ammonium hydroxide having at least one alkyl group having 3 or 4 carbon atoms, and in which exfoliated particles (C) produced by interlayer-exfoliating a proton-type layered polysilicate compound (B) are dispersed in an aqueous solution (D) having 10 vol % to 90 vol % of an alcohol having 1 to 3 carbon atoms; and a film-forming composition, a porous body-forming composition, an LB film, a coating film, a free-standing membrane, a proton conductor, an electrolyte membrane for fuel cells, and a porous body each containing exfoliated particles.

IPC Classes  ?

• C01B 33/32 - Alkali metal silicates
• H01M 8/1016 - Fuel cells with solid electrolytes characterised by the electrolyte material

Abstract

Provided is an amino acid analysis system which can continuously monitor a target amino acid, which is a target, without requiring a high-level pretreatment or an expensive analysis device. The amino acid analysis system 10 is provided with: an amino acid separation device 1 which is provided with a sample solution flow path 11 through which a sample solution containing a plurality of amino acids circulates, an extracted solution flow path 13 which is provided adjacent to the sample solution flow path 11 with, interposed therebetween, a separation membrane 12 equipped with a molecular template film through which a target amino acid can selectively pass, a pair of electrodes 14a, 14b which are provided with the sample solution flow path 12 and the extracted solution flow path 13 interposed therebetween, and a direct-current power supply 5 capable of generating a specific potential difference between the electrodes 14a, 14b; a sample solution supply device 2 which supplies the sample solution to the sample solution flow path 12; an extracted solution supply device 3A which supplies an extracted solution 13 to the extracted solution flow path; and an analysis device 4 which continuously detects the target amino acid contained in an extracted solution discharged through the extracted solution flow path 13.

IPC Classes  ?

• B01J 20/281 - Sorbents specially adapted for preparative, analytical or investigative chromatography
• B01J 20/285 - Porous sorbents based on polymers
• G01N 30/02 - Column chromatography
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

An influenza vaccine composition to be intranasally administered, including an influenza antigen to which TGDK is linked via a chemical bond.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. The serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxin is a modified from in which at least a cysteine residue located at position 73 from the N-terminal of an amino acid sequence for the thioredoxin or located at a position equivalent to the position 73 is substituted by another amino acid residue. the modified serum albumin-thioredoxin fusion body is superior in the activity and stability thereof, is reduced in immunogenicity and has superior safety compared with a fusion body in which the thioredoxin is non-modified form.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 38/38 - Albumins
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 14/765 - Serum albumin, e.g. HSA
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

Provided is a composition for treatment and the like of a disease and the like due to an intracellular cholesterol trafficking disorder which is effective as an NPC therapeutic agent, said composition being safer than conventional 2-hydroxypropyl-β-cyclodextrin while providing an equivalent or greater therapeutic effect.　This composition for treatment, prevention, or improvement of a disease or a disorder due to an intracellular cholesterol trafficking disorder contains 2-hydroxypropyl-β-cyclodextrin in which a 2-hydroxypropyl group is substituted for an OH group of β-cyclodextrin, wherein the average degree of substitution of the 2-hydroxypropyl group is 13-25.

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61P 3/06 - Antihyperlipidemics

Abstract

The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2.　A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypeptide (P1), (P2) or (P3): (P1) a polypeptide comprising an amino acid sequence represented by SEQ ID NO: 1 (KAYNVTQAF); (P2) a polypeptide comprising an amino acid sequence obtained by deleting, inserting, substituting, or adding 1-6 amino acids in the amino acid sequence represented by SEQ ID NO: 1; and (P3) a polypeptide comprising an amino acid sequence having at least 80% identity to the amino acid sequence represented by SEQ ID NO: 1.

IPC Classes  ?

• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/74 - Major histocompatibility complex [MHC]
• C07K 19/00 - Hybrid peptides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

332332366Y phase; and this magnesium alloy does not comprise a long-period stacking ordered phase. (Formula 1): a = 0.5 (0.25 ≤ b ≤ 1.2) (Formula 2): b = 1.2 (0.5 ≤ a ≤ 1.62) (Formula 3): a = 1.35b (1.2 ≤ b ≤ 3) (Formula 4): b = 3 (4.05 ≤ a ≤ 7) (Formula 5): a = 7 (0.25 ≤ b ≤ 3) (Formula 6): b = 0.25 (0.5 ≤ a ≤ 7) (Formula 7): a = 4.2b + 0.7 (0.25 ≤ b ≤ 1.5) (Formula 8): b = 0.25 (0.5 ≤ a ≤ 1.75)

IPC Classes  ?

• C22C 23/04 - Alloys based on magnesium with zinc or cadmium as the next major constituent
• C22C 23/06 - Alloys based on magnesium with a rare earth metal as the next major constituent
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon

Abstract

This image display body is obtained by sandwiching a display function layer with two transparent substrates. The display function layer contains liquid crystals, a photoisomerization material, and a transparent resin. The image display body switches between a light transmission state and a light scattering state depending on the alignment state of the liquid crystals.　The photoisomerization material contains an azobenzene compound represented by structural formula (1), and as a result, the photoisomerization material absorbs little visible light and can suppress the reduction in color reproducibility of displayed images.　In the structural formula (1), R represents an alkyl group and * represents a binding site.

IPC Classes  ?

• G02F 1/13 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells
• C09K 19/54 - Additives having no specific mesophase
• G03B 21/56 - Projection screens

Abstract

One purpose of the present invention is to provide an antibody against coronavirus (SARS-CoV-2) variants. Another purpose of the present invention is to provide a medicinal composition against coronavirus infections, the composition being based on said antibody. The present invention provides: an antibody that binds to the spike protein of coronavirus and that is capable of neutralizing coronaviruses including the omicron strain or an antigen-binding fragment thereof; and a medicinal composition that comprises said antibody or an antigen-binding fragment thereof and serves to prevent or treat coronavirus infection.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention addresses the problem of providing a recycling method for recovering a highly recyclable high-molecular-weight material from a solid mixture containing a polyester and the high-molecular-weight material by a process having a reduced environmental load and in a simple manner. The method for recycling a high-molecular-weight material comprises heating a solid mixture of a polyester and the high-molecular-weight material in the presence of water, and then separating the polyester together with water from the solid mixture by melting and recovering the high-molecular-weight material as a solid material, in which, when the melting point of the polyester in air is defined as Tm, the high-molecular-weight material has a higher melting point than Tm or, alternatively, the high-molecular-weight material has no melting point and has a solid form at Tm, and the heating is performed at a temperature of (Tm-70)°C to (Tm-10)°C inclusive.

IPC Classes  ?

• C08J 11/14 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with steam or water
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• D06M 11/05 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrogen, water or heavy waterTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrides of metals or complexes thereofTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with boranes, diboranes, silanes, disilanes, phosphines, diphosphines, stibines, distibines, arsines or diarsines or complexes thereof with water, e.g. steamTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrogen, water or heavy waterTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrides of metals or complexes thereofTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with boranes, diboranes, silanes, disilanes, phosphines, diphosphines, stibines, distibines, arsines or diarsines or complexes thereof with heavy water

Abstract

The purpose of the present invention is to provide: a novel adipocyte activator; and a use thereof. The present invention provides an adipocyte activator containing SerpinA1, a SerpinA1 expression promoter, or a SerpinA1 agonist, wherein the adipocyte is selected from among a brown preadipocyte, a brown adipocyte, and a beige adipocyte. An adipose tissue activator according to the present invention has an action that enhances a heat production action in adipose tissue, and can be used as a pharmaceutical composition for preventing and/or treating obesity and/or obesity-related diseases.

IPC Classes  ?

• A61K 38/55 - Protease inhibitors
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• G01N 33/15 - Medicinal preparations

Abstract

The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: wherein —CH2— is optionally substituted by one or two substituents, the following formula III: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: wherein —CH2— is optionally substituted by one or two substituents, the following formula III: wherein —CH2—C6H4— is optionally substituted by one or more substituents, and the following formula IV: The present invention relates to a phytic acid ester derivative and a use thereof. The phytic acid ester derivative of the present invention has a structure of the following formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently selected from the group consisting of H, the following formula II: wherein —CH2— is optionally substituted by one or two substituents, the following formula III: wherein —CH2—C6H4— is optionally substituted by one or more substituents, and the following formula IV: wherein —CH2—CH2— is optionally substituted by one or more substituents, provided that a compound where all of R1 to R12 are H is excluded.

IPC Classes  ?

• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• C07F 9/09 - Esters of phosphoric acids

Abstract

The present invention addresses the problem of developing a Staple nucleic acid that can be caused to form a guanine quadruplex structure with respect to a target nucleic acid even when a guanine repetitive sequence is not present at four locations on the target nucleic acid. The present invention also addresses the problem of developing various use applications for an existing Staple nucleic acid and the Staple nucleic acid according to the present invention.　The inventors of the present invention have solved said problems by developing an oligonucleotide (second generation Staple nucleic acid) that can be caused to form a guanine quadruplex structure on a target nucleic acid, by supplying a guanine repetitive sequence by means of the oligonucleotide, and consequently obtaining a guanine repetitive sequence at a total of four locations by guanine repeats on the target nucleic acid and the guanine repetitive sequence on the oligonucleotide. In the present invention, a new Staple nucleic acid use application has been developed for a first generation Staple nucleic acid and the second generation Staple nucleic acid.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present disclosure intends to provide an aircraft member having both high strength and good ductility. Further, the present disclosure intends to provide an aircraft member satisfying required flame resistance. Further, the present disclosure intends to provide an aircraft member satisfying required corrosion resistance. In a method of manufacturing the aircraft member according to the present disclosure, a billet of an Mg—Al—Ca based alloy is extruded at an extrusion temperature that is higher than or equal to 350° C. and lower than or equal to 400° C. and at a ram rate that is higher than or equal to 1 mm/sec and lower than or equal to 3 mm/sec.

IPC Classes  ?

• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
• C22C 23/02 - Alloys based on magnesium with aluminium as the next major constituent

Abstract

The object of the present invention is to provide: a composition for ameliorating an unpleasant state caused by menstruation, which is effective against discomfort occurring in women in the period from the first menstruation to menopause, particularly strong discomfort occurring in young women, has been sufficiently experienced as a foodstuff and has an anti-EMT activity; and a functional food containing the composition. A composition for ameliorating an unpleasant state caused by menstruation is prepared, which comprises at least one component selected from the group consisting of black rice, cherry blossom, and extracts thereof.

IPC Classes  ?

• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Abstract

It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclodextrin molecules, a single straight-chain molecule passing through the openings in the plurality of cyclodextrin molecules in a skewer-like manner, and a blocking group which is provided at both ends of the single straight-chain molecule and prevents the cyclodextrin molecules and the straight-chain molecule from separating, wherein at least some of the cyclodextrin molecules bind, via a linker, to boronic acid or a monovalent group derived therefrom.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
• C08G 65/32 - Polymers modified by chemical after-treatment
• C08G 65/337 - Polymers modified by chemical after-treatment with organic compounds containing other elements
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 31/69 - Boron compounds
• A61K 31/724 - Cyclodextrins

Abstract

The present invention addresses the problem of providing a pharmaceutical composition for use in prevention or treatment of lifestyle related diseases including type-2 diabetes and obesity related diseases.　As a solution to the problem, prepared is a pharmaceutical composition that is for use in prevention or treatment of lifestyle related diseases and that contains, as an active ingredient, a compound represented by formula (I) or a salt thereof.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

Provided are: an input device-use member with superior writing feel when an input operation is performed using an input medium, such as an input pen; an input device; and a method for manufacturing an input device-use cover member provided to the input device-use member.　The input device-use member is provided with a glass substrate 20 (input device-use cover member) and an input pen 40 (input medium) for performing input operations. At least one main surface 20a of the glass substrate 20 has bumps. The relationship 0.015 ≤ [X/Y] ≤ 1.15 is satisfied when, in the main surface 20a having said bumps, X is the average value of the size of the gap widths between bumps when the cutoff value of a high pass filter λｃis quadruple the value of the gap width between bumps of a measured corss-section curve, and Y is the diameter of the contacting portion of the pen tip 41 (tip portion) of the input pen 40 with the glass substrate 20.

IPC Classes  ?

• G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
• G06F 3/03 - Arrangements for converting the position or the displacement of a member into a coded form

Abstract

Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including a hydrophobic licorice extract containing a licorice glabra polyphenol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including a hydrophobic licorice extract containing a licorice glabra polyphenol.

IPC Classes  ?

• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including glabridin, glabrene, and glabrol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including glabridin, glabrene, and glabrol.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61P 35/00 - Antineoplastic agents
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/18 - Sulfonamides
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/47 - QuinolinesIsoquinolines

Abstract

An object is to provide a drug that effectively treats a vascular disorder caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell. Provided are [1] a therapeutic agent for a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [2] a therapeutic agent for a disease caused by excessive synthesis and secretion of a type IV collagen protein; [3] a pharmaceutical composition for treatment of a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [4] a pharmaceutical composition for treatment of a disease caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell; and [5] an agent that inhibits excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell, each of [1] to [5] containing sirolimus as an active ingredient.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

Provided is an implant magnesium alloy having corrosion resistance, mechanical strength, ductility at the same time. In one aspect of the present invention, an implant magnesium alloy contains: x at % of Zn; a total of y at % of at least one element of Ca and Sr; and the balance of Mg and inevitable impurities. x and y satisfy formulae 1 and 2: Provided is an implant magnesium alloy having corrosion resistance, mechanical strength, ductility at the same time. In one aspect of the present invention, an implant magnesium alloy contains: x at % of Zn; a total of y at % of at least one element of Ca and Sr; and the balance of Mg and inevitable impurities. x and y satisfy formulae 1 and 2: 0.15≤x≤1.5  (Formula 1) Provided is an implant magnesium alloy having corrosion resistance, mechanical strength, ductility at the same time. In one aspect of the present invention, an implant magnesium alloy contains: x at % of Zn; a total of y at % of at least one element of Ca and Sr; and the balance of Mg and inevitable impurities. x and y satisfy formulae 1 and 2: 0.15≤x≤1.5  (Formula 1) 0.5≤y≤1.5.  (Formula 2)

IPC Classes  ?

• A61L 27/04 - Metals or alloys
• A61L 31/02 - Inorganic materials
• C22C 1/02 - Making non-ferrous alloys by melting
• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
• B21C 23/00 - Extruding metalImpact extrusion
• B22F 3/20 - Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sinteringApparatus specially adapted therefor by extruding

Abstract

An object of the present invention is to provide a method for cryopreserving rat sperms and an in vitro fertilization method using cryopreserved rat sperms. The present invention provides a method for preparing cryopreserved rat sperms, characterized by comprising the following steps: step a: a preparation step of collecting rat sperms from the rat cauda epididymis to prepare a sperm suspension, step b: a cooling step of cooling the sperm suspension to about 1° C. or lower, and step c: a freezing step of freezing the rat sperm suspension cooled to about 1° C. or lower.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/076 - Sperm cellsSpermatogonia
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

Provided is an expression inhibition agent for a TRPC6 protein, the expression inhibition agent including staple nucleic acids for the TRPC6 gene.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/12 - Antihypertensives
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided are a device and the like for producing ion liquids or ion liquid raw materials of various combinations by removing and introducing ions using an electric field and membrane permeation.　A device (10) that produces ion liquids or ion liquid raw materials has a reactor (1) that has a first space (21) that contacts an anodic electrode part (31) and a first ion exchange membrane part (32) and contains a first liquid, a second space (22) that contacts the first ion exchange membrane part (32) and a second ion exchange membrane part (33) and contains a second liquid, and a third space (23) that contacts the second ion exchange membrane part (33) and a cathodic electrode part (34) and contains a third liquid, the first space (21), the second space (22), and the third space (23) being layered in that order. The ion exchange membrane parts (32, 33) both use a positive ion exchange membrane or a negative ion exchange membrane.

IPC Classes  ?

• B01D 61/42 - ElectrodialysisElectro-osmosis
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 9/21 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms two or more diaphragms
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
• C25B 1/01 - Products

Abstract

The purpose of the present invention is to provide a new marker for prostate cancer and a method for detecting prostate cancer using said marker. Provided is a method for diagnosing prostate cancer, the method comprising the steps of: (a) releasing PSA from a PSA-ACT complex present in a sample derived from a subject; (b) performing two-dimensional electrophoresis on the released PSA obtained in step (a) to isolate the PSA and detect the spot of the PSA; and (c) confirming the presence of the spot of the PSA detected on the basic side relative to the spot of the control PSA.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 27/447 - Systems using electrophoresis
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided is a therapeutic agent or the like that is for refractory viral infections and that is capable of eliminating or decreasing cccDNA in hepatocytes. This therapeutic agent for refractory viral infections according to the present invention is characterized by comprising a composite which includes, in a drug carrier useful for delivering a drug into cells, poly-I or a poly-I analog, and poly-C or a poly-C analog, and in which a molecule for providing the ability to accumulate to hepatocytes is conjugated on the surface of the carrier.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/21 - Interferons
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 31/12 - Antivirals
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

Abstract

An image processing method or the like suitable for analyzing magnetic resonance image data using simple calculation is presented. Image processing apparatus processes magnetic resonance image data acquired by scanning multiple regions of a living body. MRI imaging apparatus scanning multiple regions of the living body to acquire magnetic resonance image data. Image processing unit generates phase difference image data from the magnetic resonance image data. Signal acquisition unit acquires a phase difference image signal from the phase difference image data. Statistic calculation unit performs statistical processing of the distribution of the phase difference image signal with respect to the phase difference for each region to calculate a statistic, for example. Examples of the statistical processing includes calculation of an average, a standard deviation, kurtosis, skewness, etc. Target material evaluation unit evaluates the amount of the target material included in multiple regions using the statistic for each region.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Provided is a method which is for analyzing ionic components in pure water and in which sample ultrapure water is concentrated and analyzed by an analysis means, the method being characterized in that the sample ultrapure water is concentrated by means of an electrodialyzer. The electrodialyzer is a second electrodialyzer 20 in which sample ultrapure water is passed through a first generation chamber 27, high-purity nitric acid aqueous solution is passed through a second generation chamber 28, and concentrated water for analysis is extracted from the second generation chamber 28. The high-purity nitric acid aqueous solution passing through the second generation chamber 28 is generated by dialyzing a potassium nitrate aqueous solution with a first electrodialyzer 10.

IPC Classes  ?

• G01N 33/18 - Water

Abstract

by screening using a high-throughput evaluation system relating to the promotion of the extracellular secretion of trimers of the causative proteins COL4A3/A4/A5, which decreased in the renal tissue of patients with Alport syndrome (AS), it was found that cyclosporin A has an effect of promoting extracellular secretion of trimers of type-IV collagen. From further studies, it was found that Alisporivir and NIM258, which do not inhibit calcineurin, also have an action to promote extracellular secretion of type-IV collagen. Furthermore, the present inventors have found that these actions are based on the cyclophilin D inhibitory mechanism, and have found a radical therapeutic agent for AS by inhibition of cyclophilin D. The present invention provides a composition and an AS therapeutic/prophylactic drug, which contain a cyclophilin D inhibitor as an active ingredient, for promoting the secretion of collagen trimers in cells having a mutated type-IV collagen gene.

IPC Classes  ?

• A61K 38/13 - Cyclosporins
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Provided is a separation and purification method comprising: a step (1) for adjusting a sample solution including a first metal ion, a second metal ion, and a chelating agent to a pH at which the second metal ion chelates to form a complex having a negative charge, while the first metal ion essentially does not chelate; a step (2-1) for bringing a solution containing the first metal ion and the chelated second metal ion obtained in step (1) into contact with a cation exchange body, and adsorbing the first metal ion in the solution on the cation exchange body to remove the first metal ion; a step (2-2) for obtaining a treated solution containing the chelated second metal ion, from which the first metal ion has been removed; and a step (3) for decomposing the chelating agent for the chelated second metal ion contained in the treated solution obtained in step (2-2), to obtain a purified second metal ion. This separation and purification method is suitable when the second metal is a radioisotope obtained by conversion from the first metal.

IPC Classes  ?

• G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• B01J 39/05 - Processes using organic exchangers in the strongly acidic form
• B01J 39/07 - Processes using organic exchangers in the weakly acidic form
• B01J 39/09 - Inorganic material
• B01J 39/20 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 39/22 - Cellulose or woodDerivatives thereof
• B01J 47/02 - Column or bed processes
• B01J 47/14 - Controlling or regulating
• B01J 49/00 - Regeneration or reactivation of ion-exchangersApparatus therefor
• B01J 49/20 - Regeneration or reactivation of ion-exchangersApparatus therefor of membranes

Abstract

Provided herein is a pharmaceutical composition for treating cancer, the pharmaceutical composition containing: a folic acid-modified hydroxyalkylated cyclodextrin selected from the group consisting of folic acid-modified hydroxypropylcyclodextrin, folic acid-modified hydroxybutylcyclodextrin, and folic acid-modified hydroxyethyl cyclodextrin; or a derivative thereof. Thus, a novel pharmaceutical composition for treating cancer and the like is provided.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I): Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I): Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I): wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

IPC Classes  ?

• A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils

Abstract

CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.

IPC Classes  ?

• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• C07D 221/20 - Spiro-condensed ring systems
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral

Abstract

A method for analyzing a modified nucleoside according to the present invention comprises: an elution step for introducing a sample containing a target component that is a modified nucleoside of which the hydrophobicity is increased by modification and a reference component that is a different component from the target component into a liquid chromatography column, and then separating the target component and the reference component from each other and eluting the target component and the reference component from the column by gradient elution such that the mixing ratio of a plurality of solvents constituting a mobile phase is changed over time; a step for detecting the target component and the reference component separately by mass spectrometry; and a step for calculating the ratio of a detected value for the target component to a detected value for the reference component. In the elution step, the mixing ratio of the solvents constituting the mobile phase to be introduced into the column is changed in such a manner that a third period in which the change ratio of the mixing ratio of the solvents constituting the mobile phase as measured at an outlet port of the column is larger than that in a first period in which the target component is eluted from the column and that in a second period in which the reference component is eluted from the column is provided between the first period and the second period.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/58 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving urea or urease
• C12Q 1/62 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving uric acid
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6872 - Methods for sequencing involving mass spectrometry
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• B01J 20/287 - Non-polar phasesReversed phases
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 30/26 - Conditioning of the fluid carrierFlow patterns
• G01N 30/34 - Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
• G01N 30/50 - Conditioning of the sorbent material or stationary liquid
• G01N 30/72 - Mass spectrometers
• G01N 30/86 - Signal analysis
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The purpose of the present invention is to provide a novel therapeutic agent for dyslipidemia, which targets angiopoietin-like factor 3. According to the present invention, a vaccine composition is provided, which contains a peptide having a portion of the sequence for angiopoietin-like factor 3 (ANGPTL3) as an active ingredient, in which the peptide comprises at least one peptide selected from the group consisting of EPKSRFA (SEQ ID NO: 3), EPKSRFAMLD (SEQ ID NO: 4) and EPKSRFAMLDDVK (SEQ ID NO: 5).

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 19/00 - Hybrid peptides

Abstract

The present invention provides: a compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition that is to be used for inhibiting metallo-β-lactamase and that contains said compound or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 499/68 - Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms with aromatic rings as additional substituents on the carbon chain
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61P 31/04 - Antibacterial agents
• C07D 477/24 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 6
• C07D 501/28 - Methylene radicals, substituted by oxygen atomsLactones thereof with the 2-carboxyl group with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
• C07D 501/30 - Methylene radicals, substituted by oxygen atomsLactones thereof with the 2-carboxyl group with the 7-amino-radical acylated by an araliphatic carboxylic acid

Abstract

An electric pulse decomposition method for separating a composite material by an electric pulse, the composite material being obtained by bonding or joining a plurality of conductors to each other with an insulating member, the electric pulse decomposition method including a protrusion formation step for forming a protrusion in a specific site, on a side on which the composite material is arranged, of at least one of the plurality of conductors, and a separation step for separating the plurality of conductors in the composite material 1 by respectively bringing electrodes into contact with surfaces of the plurality of conductors and applying an electric pulse between the electrodes to destroy the insulating member. This makes it possible to separate the plurality of conductors from the composite material by making a shock wave caused by a current of the dielectric breakdown functioning as an adhesive to effectively destroy the insulating member.

IPC Classes  ?

• B02C 19/18 - Use of auxiliary physical effects, e.g. ultrasonics, irradiation, for disintegrating
• H01B 7/38 - Insulated conductors or cables characterised by their form with arrangements for facilitating removal of insulation

Abstract

The purpose of the present invention is to provide a novel agent for the prevention or treatment of muscular atrophy. The present invention provides an agent for the prevention or treatment of muscular atrophy, wherein the agent contains a Dll4 function inhibitor as an active ingredient. The Dll4 function inhibitor is selected from the group consisting of inhibitors of binding between Dll4 and Notch2, inhibitors of the expression of Dll4, or inhibitors of binding of collagen with LL4.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an influenza vaccine for transnasal administration which is efficiently taken up though the nasal mucosa.　This influenza vaccine composition for transnasal administration contains an influenza antigen to which TGDK is linked via a chemical bond.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 9/08 - Solutions
• A61K 9/14 - Particulate form, e.g. powders
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units

Abstract

Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. A serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxin is a modified form in which at least a cysteine residue located at position-73 from the N-terminal of an amino acid sequence for the thioredoxin or located at a position equivalent to the position-73 is substituted by another amino acid residue. The serum albumin-thioredoxin fusion body is superior in the activity and stability thereof, is reduced in immunogenicity and has superior safety compared with a fusion body in which the thioredoxin is a non-modified form.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• A61P 39/06 - Free radical scavengers or antioxidants
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/765 - Serum albumin, e.g. HSA
• C07K 19/00 - Hybrid peptides
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/14 - Human serum albumins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The purpose of the present invention is to provide a method for identifying a subject who is or may be suffering from COVID-19. The present invention provides a method for identifying whether or not a mammal subject is or may be suffering from COVID-19, the method comprising detecting the level of at least one modified nucleoside selected from the group consisting of 6-threonylcarbamoyladenosine (t6A) and 2-thiomethyl,6-threonylcarbamoyladenosine (ms2t6A) in a sample derived from the subject.

IPC Classes  ?

• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode

Abstract

The present invention provides a pharmaceutical composition for use in the reactivation of HIV latent infection, the pharmaceutical composition containing compounds represented by formulae (I)-(VII).

IPC Classes  ?

• A61K 31/225 - Polycarboxylic acids
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This image processing method includes: a step in which a vascular mask creating unit creates a vascular mask image by subjecting an image, obtained from a magnetic resonance signal obtained by enhancing regions corresponding to blood vessels in an MRI image, to removal of dot-shaped low signals, removal of linear low signals, extraction of linear low signals, removal of dot-shaped high signals, removal of linear high signals, and extraction of linear high signals; and a step in which a mask processing unit generates an image obtained by employing the vascular mask image to remove a vascular structure from a phase difference enhanced image created from the MRI image.

IPC Classes  ?

• G06T 1/00 - General purpose image data processing
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

[Problem] To provide a dispersion of exfoliated particles in which a layered polysilicate compound is interlayer-exfoliated. [Solution] Provided are: a dispersion of exfoliated particles which includes at least one nitrogen-containing basic compound (A) which is a tertiary amine or a quaternary ammonium hydroxide having at least one alkyl group having 3 or 4 carbon atoms, and in which exfoliated particles (C) produced by interlayer-exfoliating a proton-type layered polysilicate compound (B) are dispersed in an aqueous solution (D) having 10 vol% to 90 vol% of an alcohol having 1 to 3 carbon atoms; and a film-forming composition , a porous body-forming composition , an LB film, a coating film, a self-supporting film, a proton conductor, an electrolyte membrane for fuel cells, and a porous body each containing exfoliated particles.

IPC Classes  ?

• C01B 33/38 - Layered base-exchange silicates, e.g. clays, micas or alkali metal silicates of kenyaite or magadiite type
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/1016 - Fuel cells with solid electrolytes characterised by the electrolyte material

Abstract

Provided is a plant parasitic nematode controlling agent based on a new plant parasitic nematode resistant gene.　The plant parasitic nematode controlling agent comprises: (a) an amino acid sequence represented by SEQ ID NO. 1; (b) an amino acid sequence resulting from deletion, substitution, or addition of one or more amino acid residues in the amino acid sequence represented by SEQ ID NO. 1; or (c) a polypeptide having any one of amino acid sequences indicating an identity of 90% or more with respect to the amino acid sequence represented by SEQ ID NO. 1, or a fragment of said polypeptide.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01P 5/00 - Nematocides
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

The present invention provides an aminated polyrotaxane (PRX) (amino-PRX) carrier as a nucleic acid/protein carrier. Amino-PRX freely provides an amino group to the sgRNA and acidic amino acids of Cas9. A polyplex with Cas9 RNP (automatic molecular imprinting) was efficiently and easily formed by rotating and moving CD merely by mixing amino-PRX and Cas9 RNP, resulting in efficient intracellular delivery of Cas9 RNP. Furthermore, structural optimization of the axis/end cap linker and the amino group/CD linker made it possible to realize strict control of the intracellular dynamics of Cas9 RNP and high efficiency in genome editing.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 38/46 - Hydrolases (3)
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

An object of the present invention is to provide a means for fixing a pancreatic resection stump created during an operation for resecting a portion of the pancreas. The present invention provides a polymeric surgical clip characterized in that the clip comprises a first arm portion, a second arm portion, and a resilient hinge portion joining the first and second arm portions together, both the arm portions are joined to the resilient hinge portion at their bases, the first arm portion has a convex outer surface and a concave inner surface clamping the pancreas, the second arm portion has a convex or flat outer surface and a concave or flat inner surface clamping the pancreas, the first arm portion forms at its distal end a deflectable hook portion curved toward the second arm portion, and the clip is configured so that, in a closed position, a distal end of the second arm portion enters inside the curved hook portion and engages with the hook portion to lock the clip in the closed position.

IPC Classes  ?

• A61B 17/08 - Wound clamps
• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines

Abstract

Provided are: a cover member for an input device with which it is possible to produce an excellent writing feel during an input operation performed on a pen input device using an input pen; and a pen input device.　In the present invention: the dynamic friction coefficient μk(Elastomer) during the 99th movement when a friction piece made of an elastomer to which a load of 200 gf is imparted is reciprocatingly moved 100 times on the main surface of a cover member at a movement distance of 50 mm and a movement speed of 50 mm/s in room temperature is in the range of 0.15-0.6; the dynamic friction coefficient μk(POM) during the 99th movement when a friction piece made of POM to which a load of 200 gf is imparted is reciprocatingly moved 100 times on the main surface of the cover member at a movement distance of 50 mm and a movement speed of 50 mm/s in room temperature is in the range of 0.15-0.6; and the dynamic friction coefficient ratio (μk(Elastomer)/μk(POM)) is in the range of 1.0-3.0.

IPC Classes  ?

• C03C 19/00 - Surface treatment of glass, not in the form of fibres or filaments, by mechanical means
• G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means

Abstract

Provided are a sensor device and the like suitable for wiring of a flexible sol-gel composite piezoelectric sensor. In a sensor device 1, a sensor portion 3 and a wiring portion 5 are connected to one another. The sensor portion 3 is a sol-gel composite piezoelectric sensor. The sensor portion 3 is provided with a base material layer, a piezoelectric film layer formed on the base material layer, an electrode layer formed on the piezoelectric film layer, and a protective layer. The protective layer covers the base material layer and the electrode layer, excluding a portion thereof. The wiring portion 5 includes a signal line and a ground line. There is a pressure bonding tip at the tip end of the signal line. An upper exterior portion 7 and a lower exterior portion 9 cover at least the parts of the sensor portion 3 and the wiring portion 5 that are not covered. A pressing portion 11 pressure bonds the pressure bonding tip by pressing the same against the part of the electrode layer not covered by the protective layer. The sensor device can, for example, be attached to an inspection target using an attachment that covers the sensor portion, for example.

IPC Classes  ?

• G01L 1/16 - Measuring force or stress, in general using properties of piezoelectric devices
• H01L 41/047 - Electrodes
• H01L 41/053 - Mounts, supports, enclosures or casings
• H01L 41/113 - Piezo-electric or electrostrictive elements with mechanical input and electrical output
• H01L 41/187 - Ceramic compositions
• H01L 41/23 - Forming enclosures or casings
• H01L 41/29 - Forming electrodes, leads or terminal arrangements
• H01L 41/318 - Applying piezo-electric or electrostrictive parts or bodies onto an electrical element or another base by depositing piezo-electric or electrostrictive layers, e.g. aerosol or screen printing by liquid phase deposition by sol-gel deposition

Abstract

An electrode device includes a first electrode, a second electrode, and an ion-conducting medium extending over and in contact with the first electrode and the second electrode. The ion-conducting medium is made of a bicontinuous microemulsion including a water phase as a continuous phase and an oil phase as a continuous phase. At least one of the water phase and the oil phase is a gel.

IPC Classes  ?

• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/48 - Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage

Abstract

An exemplary method can be provided for producing ureteric bud cells from pluripotent stem cells, in vitro. Further, an exemplary method can be provided for producing ureteric bud cells and Wolffian duct (WD) progenitor-like cells that are a progenitor of the ureteric bud cells. Another exemplary method can be provided for producing Wolffian duct (WD) progenitor-like cells that can comprise obtaining C-X-C chemokine receptor 4 (CXCR4) positive and KIT proto-oncogene receptor tyrosine kinase (KIT) positive cells. In addition, an exemplary method can be provided for producing ureteric-bud-like cells using WD progenitors that are CXCR4+ and KIT+, and another exemplary method can be provided for producing kidney organoids in which the ureteric-bud-like cells can be used.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

There is provided a method for suppressing protein expression, including using an oligomer for RNA having first, second, third, and fourth guanine repeat sequences (referred to as “first G sequence,” “second G sequence,” “third G sequence,” and “fourth G sequence,” respectively), the oligomer hybridizing with regions proximal to the guanine repeat sequences, so as to bring the guanine repeat sequences closer together, thereby forming a guanine-quadruplex structure.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/67 - General methods for enhancing the expression
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

Provided are: a transthyretin tetramer stabilizing agent; and a transthyretin amyloidosis preventing agent or progression suppressing agent.　The present invention relates to a transthyretin tetramer stabilizing agent containing a Glycyrrhiza glabra hydrophobic extract that includes Glycyrrhiza-glabra glabra polyphenol, and also to a transthyretin amyloidosis preventing agent or progression suppressing agent containing a Glycyrrhiza glabra hydrophobic extract that includes Glycyrrhiza-glabra glabra polyphenol.

IPC Classes  ?

• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

Provided are a transthyretin tetramer stabilizer and an agent for preventing or suppressing the progress of transthyretin amyloidosis.　The present invention relates to a transthyretin tetramer stabilizer containing glabridin, glabrene, and glabrol and an agent for preventing or suppressing the progress of transthyretin amyloidosis, the agent containing glabridin, glabrene, and glabrol.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

An exemplary substance is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Further, exemplary use of the substance as a drug carrier is provided for delivering into the brain, and a pharmaceutical composition containing the substance. Additionally, exemplary lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Exemplary blood-brain barrier permeable pharmaceutical composition is also provided which comprises a lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin, and a drug.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a very unpleasant feeling felt by young females, having anti-EMT activity, and being sufficiently experienced as foodstuff; and a functional food containing said composition.　According to the present invention, a composition, which is for ameliorating an unpleasant state caused by menstruation and contains at least one selected from the group consisting of black rice, cherry, and extracts thereof, is prepared.

IPC Classes  ?

• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61P 1/12 - Antidiarrhoeals
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 7/06 - Antianaemics
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

One purpose of the present invention is to provide an antibody against a coronavirus (SARS-CoV-2). Another purpose of the present invention is to provide a pharmaceutical composition against the coronavirus using said antibody. The present invention provides: an antibody or an antigen-binding fragment thereof that binds to the receptor binding domain present in the spike protein of a coronavirus and that is capable of neutralizing the coronavirus; and a pharmaceutical composition containing said antibody or an antigen-binding fragment thereof, for prevention or treatment of coronavirus infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

6 alkoxy group, or the like; X represents an oxygen atom; Y represents a substituent; q represents any integer of 0 to 3; n represents 0 or 1; and m represents 0 or 1.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings

Abstract

A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention has an object of providing a novel peptide that is permeable to the blood-brain barrier. The present invention provides a blood-brain barrier permeable peptide containing an amino acid sequence: SLSHSPQ (SEQ ID NO: 1) (where P may be substituted). The present invention also provides a carrier molecule for intracerebral delivery containing the peptide, a complex composed of the peptide and a target molecule that is allowed to permeate the blood-brain barrier, and a blood-brain barrier permeable composition containing the complex.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/107 - Emulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/50 - Microcapsules

Abstract

The present inventors have conducted intensive studies on an antibody which controls HIV in an administration group with a high probability over a long period of time with one or several times of single-agent administration. As a result, the present inventors have surprisingly found that, when an SW-1C10 antibody, which is obtained by producing an antibody gene reported as 1C10 in silkworms, is singly administered only a few times, the viral load in the blood is suppressed to the detection limit or lower at an early stage in all of individuals to which the antibody has been administered, and moreover, the viral RNA load in the blood is maintained at the detection limit or lower for a long time of 12 weeks. Also, the yield of the antibody in silkworms is approximately several hundreds μg per cocoon, or several μg per 1 mg of cocoon, and studies to increase the productivity more than this level have not been conducted heretofore. The present inventors have conducted studies to find an antibody having a higher yield in silk-spinning insects among a large number of anti-HIV antibodies. As a result, the present inventors have found that a 1C10 antibody and a 1D9 antibody, each of which is an anti-HIV antibody, are produced in silk threads of silk-spinning insects at a higher yield than the conventional yield.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A01K 67/04 - Silkworms

Abstract

Provided are: a repeat binding agent containing a cyclic pyrrole-imidazole polyamide that targets a repetitive sequence that includes A or T and that causes repeat diseases; and a pharmaceutical composition containing said binding agent.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a scFv comprising a heavy chain variable region (VH) and a light chain variable region linked by a first peptide linker, wherein an N-terminus and a C-terminus thereof are linked by a second peptide linker.

IPC Classes  ?

• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 9/52 - Proteinases derived from bacteria

Abstract

The present invention provides a novel heat exchange medium to replace lead. A carbon-steel wire 1A heated in a heating furnace 11 is passed through a bath 12A filled with a liquid-phase Mg—Al—Ca alloy 20 obtained by melting a Mg—Al—Ca alloy in which the main constituent elements are Mg (magnesium), Al (aluminum) and Ca (calcium). When it passes through the bath 12A, the carbon-steel wire 1A, which has been heated for example to about 950° C. in the heating furnace 11, is cooled to about 550° C. The Mg—Al—Ca alloy is non-toxic and has no environmental impact as well.

IPC Classes  ?

• C21D 9/64 - Patenting furnaces
• C22C 23/02 - Alloys based on magnesium with aluminium as the next major constituent
• C22C 21/00 - Alloys based on aluminium
• C22C 30/00 - Alloys containing less than 50% by weight of each constituent
• C21D 1/48 - Metal baths

Abstract

Provided is a medical agent for effectively treating a vascular disorder caused by the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells.?Provided are [1] a therapeutic agent for a vascular disorder associated with the excessive synthesis and secretion of type IV collagen protein, [2] a therapeutic agent for diseases caused by the excessive synthesis and secretion of type IV collagen protein, [3] a pharmaceutical composition for treating a vascular disorder associated with the excessive synthesis and secretion of type IV collagen protein, [4] a pharmaceutical composition for treating diseases caused by the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells, and [5] an agent for inhibiting the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells, each of which contains sirolimus as an active ingredient.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

Provided is a medical agent for effectively treating a vascular disorder caused by the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells.　Provided are [1] a therapeutic agent for a vascular disorder associated with the excessive synthesis and secretion of type IV collagen protein, [2] a therapeutic agent for diseases caused by the excessive synthesis and secretion of type IV collagen protein, [3] a pharmaceutical composition for treating a vascular disorder associated with the excessive synthesis and secretion of type IV collagen protein, [4] a pharmaceutical composition for treating diseases caused by the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells, and [5] an agent for inhibiting the excessive synthesis and secretion of type IV collagen protein from vascular endothelial cells, each of which contains sirolimus as an active ingredient.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a magnesium alloy for implants that simultaneously exhibits corrosion resistance, mechanical strength, and ductility. An embodiment of the present invention is a magnesium alloy for implants that contains x atomic% of Zn and y atomic% for the total of at least one element selected from Ca and Sr, wherein the balance comprises Mg and inevitable impurities. x and y satisfy the following (formula 1) and (formula 2): (formula 1) 0.15 ≤ x ≤ 1.5 and (formula 2) 0.5 ≤ y ≤ 1.5.

IPC Classes  ?

• B21C 23/00 - Extruding metalImpact extrusion
• C22C 23/04 - Alloys based on magnesium with zinc or cadmium as the next major constituent
• C22C 1/02 - Making non-ferrous alloys by melting
• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• A61L 27/04 - Metals or alloys
• B22F 3/20 - Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sinteringApparatus specially adapted therefor by extruding

Abstract

Proposed is an image processing method and the like suitable for an analysis of magnetic resonance image data through simple arithmetic processing. An image processing device 5 performs processing on magnetic resonance image data obtained by capturing images of a plurality of sites of a living body. An MRI scanner 3 captures images of a plurality of sites of a living body to obtain magnetic resonance image data. An image processing unit 11 generates phase difference image data from the magnetic resonance image data. A signal acquisition unit 13 acquires phase difference image signals from the phase difference image data. A statistic calculation unit 15 calculates, for example, a statistic by performing statistical processing on the distribution of the phase difference image signals against phase difference on a per-site basis. The statistical processing involves, for example, calculation of a mean, a standard deviation, kurtosis, and skewness. A target substance evaluation unit 17 evaluates the amount of a target substance contained in the plurality of sites, using the statistic calculated on a per-site basis.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

6 alkoxy group, or the like; X represents an oxygen atom; Y represents a substituent; q represents any integer of 0 to 3; n represents 0 or 1; and m represents 0 or 1.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings

Abstract

[Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Abstract

Provided is a magnesium alloy having a thermal conductivity of 75 W/m・K or more and a high specific strength. One aspect of the present invention is a magnesium alloy containing a at.% of AI, b at.% of Ca, c at.% of Mn, and d at.% of D, with the remainder comprising Mg and unavoidable impurities. D has at least one of a rare-earth element (RE), Sn, Li, Zn, Ag, Be and Sc. The magnesium alloy does not contain Si and Sr. C mentioned above satisfies expression 1 below, d satisfies expression 2 below, and a and b are within a range enclosed by the solid line shown in fig. 1. The thermal conductivity is 75 W/m・K or greater. (Expression 1) 0≤c≤0.1 (Expression 2) 0≤d≤1

IPC Classes  ?

• C22C 23/00 - Alloys based on magnesium
• C22C 47/14 - Making alloys containing metallic or non-metallic fibres or filaments by powder metallurgy, i.e. by processing mixtures of metal powder and fibres or filaments
• C22C 49/04 - Light metals
• C22C 49/12 - Intermetallic matrix material
• C22C 1/00 - Making non-ferrous alloys
• C22C 1/02 - Making non-ferrous alloys by melting
• C22C 1/10 - Alloys containing non-metals
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B22F 3/105 - Sintering only by using electric current, laser radiation or plasma
• B22F 3/16 - Both compacting and sintering in successive or repeated steps

Abstract

The purpose of the present invention is to provide a rat sperm freezing method and an in vitro fertilization method that uses frozen rat sperm. The present invention provides a method for preparing frozen rat sperm. The method is characterized by including the following steps. Step a: a preparation step for collecting rat sperm from rat cauda epididymides and preparing a sperm suspension; step b: a cooling step for cooling the sperm suspension to approximately 1°C or below; and step c: a freezing step for freezing the rat sperm suspension that has been cooled to approximately 1°C or below.

IPC Classes  ?

• C12N 5/076 - Sperm cellsSpermatogonia
• A01K 67/02 - Breeding vertebrates
• A01N 1/00 - Preservation of bodies of humans or animals, or parts thereof
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The purpose of the present invention is to provide a pharmaceutical composition for treating lipid storage disorder. More specifically, the purpose of the present invention is to provide a pharmaceutical composition for treating lipid storage disorder, the pharmaceutical composition exhibiting a therapeutic effect by improving lipid storage at least in the brain. According to the present invention, there is provided a pharmaceutical composition for treating the storage of lipids in the brain, the pharmaceutical composition containing lactose-modified hydroxypropyl-β-cyclodextrin or lactose-modified hydroxypropyl-γ-cyclodextrin as an active ingredient, wherein the pharmaceutical composition is characterized in that the compound migrates at least into the brain when administered in vivo.

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided is a combination of additive elements for a magnesium alloy, which can improve an ignition point while preventing the occurrence of internal oxidation during dissolution. One aspect of the present invention is a non-combustible magnesium alloy which contains A, B and Be in amounts falling within the ranges that satisfy formulae 1 to 3, with the remainder comprising Mg and unavoidable impurities, wherein A represents an element that is likely to be formed into an oxide compared with magnesium and comprises at least one element selected from Ca, Sc and RE (a rare earth element), and B represents an element that is less likely to be formed into an oxide compared with magnesium and comprises at least one element selected from Al, Zn, Mn, Sn, Ag and Sr.　(Formula 1) 0.3 at% ≤ A ≤ 10 at% (Formula 2) 0 at% ≤ B ≤ 11 at% (Formula 3) 0.003 at% ≤ Be ≤ 0.1 at%

IPC Classes  ?

• B22D 21/00 - Casting non-ferrous metals or metallic compounds so far as their metallurgical properties are of importance for the casting procedureSelection of compositions therefor
• B22D 21/04 - Casting aluminium or magnesium
• B22D 27/04 - Influencing the temperature of the metal, e.g. by heating or cooling the mould
• C22C 23/00 - Alloys based on magnesium
• C22C 23/02 - Alloys based on magnesium with aluminium as the next major constituent
• C22C 23/04 - Alloys based on magnesium with zinc or cadmium as the next major constituent
• C22C 23/06 - Alloys based on magnesium with a rare earth metal as the next major constituent
• C22C 1/02 - Making non-ferrous alloys by melting
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon

Abstract

A pathological mechanism in FOP patients is further revealed, and development of a novel therapeutic drug, therapeutic method, diagnostic method, etc. utilizing an obtained finding is provided. The inventors have found a novel finding that in FOP, ectopic ossification, which occurs by an inflammation due to an injury, etc., is mediated by PAR1 to occur. From this finding, the inventors completed the present invention relating to a drug, etc. characterized by suppressing ectopic ossification in FOP by inhibiting PAR1.

IPC Classes  ?

• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

An insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by formula (I): (in the formula, R1, R2, and R3 each represent a saturated fatty acid residue, and at least one thereof is a pentadecanoic acid residue). It was found that pentadecanoic acid triglyceride has an insulin secretion-promoting action during increase of blood sugar level. Provided are a pharmaceutical product and health food for improving the blood sugar level and improving diabetes by using this triglyceride.

IPC Classes  ?

• A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A61K 36/02 - Algae
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A purpose of the present invention is to provide an incubator device and the like capable of performing measurements in a manner such as to minimize changes in the state of a medium. The incubator device is designed to control the cell culture environment and includes an airtight housing, a light source for irradiating a medium containing seeded cells with light, a light measurement unit for measuring the intensity of light from the medium, and a light guide member for guiding the light from the medium to the light measurement unit. The light source unit, the light measurement unit and the light guide member are placed within the housing.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors